Ritonavir, an approved HIV protease inhibitor, was reported to bind cytomegalovirus immediate-early protein IE1 and drive ubiquitin-proteasome-mediated degradation, blocking viral replication in the study. The work describes synergy with ganciclovir, suggesting ritonavir’s impact may complement standard CMV therapeutics rather than replace them. For antiviral discovery teams, the protein-target mechanism adds mechanistic plausibility that can support further translational evaluation of ritonavir or ritonavir-derived compounds in CMV management.